Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study

• Published in: Supportive care in cancer 2021-11, Vol.29 (11), p.6253-6258
• Main Authors: Cathcart-Rake, Elizabeth J., Zahrieh, David, Smith, Deanne, Young, Susan, McCue, Shaylene, O’Connor, Amanda, Thomé, Stephan, Lacouture, Mario, Register, Terra, Piens, Jill, Friday, Bret B., Loprinzi, Charles L.
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Breast Neoplasms - drug therapy; Cancer; Cancer therapies; Chemotherapy; Clinical trials; Confidence intervals; Docetaxel - adverse effects; Female; Humans; Medicine; Medicine & Public Health; Minnesota; Monoclonal antibodies; Neoplasms - drug therapy; Nose; Nursing; Nursing Research; Oncology; Oncology, Experimental; Original Article; Paclitaxel - adverse effects; Pain; Pain Medicine; Patients; Questionnaires; Rehabilitation Medicine; Side effects; Symptom management; Targeted cancer therapy
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-021-06190-0

Purpose To describe the natural history of nasal vestibulitis in patients receiving taxane chemotherapy, including incidence, severity, and associated symptoms. Methods Eligible patients with minimal or no baseline nasal symptoms were enrolled in this natural history study at initiation of a new chemotherapy regimen. Patients completed nasal symptom logs each time they received a chemotherapy dose. This manuscript reports upon the patients who received paclitaxel, docetaxel, or non-taxane non-bevacizumab chemotherapy. The proportions of patients within each cohort reporting any treatment-emergent nasal symptoms were estimated, with corresponding exact 95% confidence intervals. A cumulative incidence function was estimated within the chemotherapy cohorts to calculate the cumulative incidence rate of treatment-emergent nasal vestibulitis, treating death and disease progression as competing risks. Results Of the 81 evaluable patients, nasal symptoms were reported by 76.5% (58.8%, 89.3%) receiving paclitaxel, 54.2% (32.8%, 74.5%) receiving docetaxel, and 47.8% (26.8%, 69.4%) receiving non-taxane and non-bevacizumab chemotherapy. Of the three pairwise chemotherapy group comparisons, both the tests comparing the cumulative incidence function between the paclitaxel and non-taxane non-bevacizumab chemotherapy cohorts and between the paclitaxel and docetaxel cohorts achieved statistical significance at the 5% level with a higher incidence of treatment-emergent nasal vestibulitis in the paclitaxel cohort in both comparisons ( P = 0.026 and P = 0.035, respectively). These significant differences were retained in the cumulative incidence function regression analysis controlling for age, smoking history, allergies, and asthma. Most patients in the paclitaxel cohort reported nasal symptoms as moderate or severe (56%). Conclusion Patients receiving paclitaxel chemotherapy experience a high incidence of nasal symptoms.